Appropriate use of β-lactam - β-lactamase inhibitor combination antibiotics
05/07/24 • 53 min
The rampant emergence of antimicrobial resistance, particularly amongst Gram negative organisms, has called for both the discovery of novel agents but also for a review of therapeutics thought to have been long lost in this battle. Enter, the "BLBLIs or BLICs'. In this episode Vin and Ruan speak with the 1st author of the publication "Appropriate use of the new β-lactam - β-lactamase inhibitor combination agents: Ceftazidime-avibactam and Ceftolozane-tazobactam in South Africa", Professor Adrian Brink, and receive a welcomed masterclass on this interesting group of antimicrobials.
About our Guest:
Professor Adrian Brink is Head of the Division: Medical Microbiology, and member of the Institute of Infectious Disease & Molecular Medicine, Faculty of Health Sciences, University of Cape Town and the National Health Laboratory Services, Groote Schuur hospital, Cape Town, South Africa.
Prof Brink was founding President of the Federation of Infectious Diseases Societies of Southern Africa and is the founder and currently co-chairs the South African Antibiotic Stewardship Program (SAASP). Prof Brink currently serves on the South African Minister of Health’s Ministerial Advisory Committee (MAC) on Antimicrobial Resistance and representing Africa, is a member of the European Society of Clinical Microbiology and Infectious Diseases International Affairs Subcommittee.
His is main research interests are the clinical and molecular epidemiology of antibiotic-resistant infections, the mechanisms of resistance as a confounder in antibiotic stewardship, the design and implementation of large-scale antibiotic stewardship, diagnostic stewardship and infection prevention and control interventions in low- and middle-income countries. His interests also include the protective, metabolic and immune functions of the gastrointestinal and vaginal biome including the resistome and metabolome.
Resources from this episode
Table 1: Data on inhibitor classes, inhibitory mechanisms, and current clinical trial status, Kar D et al., 2023.
Visit the Microbe Mail website to sign up for updates
Follow on:
Instagram: Microbe_Mail
X/Twitter: @microbemail
Facebook: MicrobeMail
Tiktok: @microbe.mail
Watch this episode on our new YouTube channel: Microbe Mail
E-mail us: [email protected]
-WE'D LOVE YOUR FEEDBACK ON THIS EPISODE –
The rampant emergence of antimicrobial resistance, particularly amongst Gram negative organisms, has called for both the discovery of novel agents but also for a review of therapeutics thought to have been long lost in this battle. Enter, the "BLBLIs or BLICs'. In this episode Vin and Ruan speak with the 1st author of the publication "Appropriate use of the new β-lactam - β-lactamase inhibitor combination agents: Ceftazidime-avibactam and Ceftolozane-tazobactam in South Africa", Professor Adrian Brink, and receive a welcomed masterclass on this interesting group of antimicrobials.
About our Guest:
Professor Adrian Brink is Head of the Division: Medical Microbiology, and member of the Institute of Infectious Disease & Molecular Medicine, Faculty of Health Sciences, University of Cape Town and the National Health Laboratory Services, Groote Schuur hospital, Cape Town, South Africa.
Prof Brink was founding President of the Federation of Infectious Diseases Societies of Southern Africa and is the founder and currently co-chairs the South African Antibiotic Stewardship Program (SAASP). Prof Brink currently serves on the South African Minister of Health’s Ministerial Advisory Committee (MAC) on Antimicrobial Resistance and representing Africa, is a member of the European Society of Clinical Microbiology and Infectious Diseases International Affairs Subcommittee.
His is main research interests are the clinical and molecular epidemiology of antibiotic-resistant infections, the mechanisms of resistance as a confounder in antibiotic stewardship, the design and implementation of large-scale antibiotic stewardship, diagnostic stewardship and infection prevention and control interventions in low- and middle-income countries. His interests also include the protective, metabolic and immune functions of the gastrointestinal and vaginal biome including the resistome and metabolome.
Resources from this episode
Table 1: Data on inhibitor classes, inhibitory mechanisms, and current clinical trial status, Kar D et al., 2023.
Visit the Microbe Mail website to sign up for updates
Follow on:
Instagram: Microbe_Mail
X/Twitter: @microbemail
Facebook: MicrobeMail
Tiktok: @microbe.mail
Watch this episode on our new YouTube channel: Microbe Mail
E-mail us: [email protected]
-WE'D LOVE YOUR FEEDBACK ON THIS EPISODE –
Previous Episode
HIV in South Africa: Part 2
Professor Francois Venter is back in Part 3 of our HIV series in which he continues to address South Africa's battles against HIV. Here he discusses his experience on how and when to initiate antiretroviral therapy, prophylaxis against opportunistic infection, routine monitoring and what the future of HIV management looks like in South Africa.
About our Guest:
Professor WD Francois Venter, MD, FCP, PhD is Executive Director of Wits Ezintsha at the University of the Witwatersrand, Johannesburg, where he received most of his training. His work involves health systems research and clinical trials, most recently involving the antiretrovirals dolutegravir, tenofovir alafenamide, cabotegravir, and doravirine. He leads multiple antiretroviral treatment optimisation studies and is currently working on new access programmes through private pharmacies within South Africa, patient linkage-to-care interventions, self-testing projects, as well as most recently on new large-scale primary care delivery platforms addressing hypertension, diabetes, obesity, hyperlipidaemia and HIV. He has led large PEPFAR-funded HIV programmes in South Africa, focusing on men, women, children, young people, truckers, sex workers, and LGBTI communities. For over 20 years he has been an advisor to bodies such as the South African government, UNAIDS, and WHO, contributing to international, regional, and national HIV guidelines, and recently served as a member of the Ministerial Advisory Committee for COVID-19. He has an active interest in medical ethics and has been involved in several HIV-related human rights cases within the southern African region. He supervises Masters and PhD students and has over 200 publications, including first-author articles in major journals.
Resources:
Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults:2023 update
Liverpool HIV Drug Interactions Checker
Visit the Microbe Mail website to sign up for updates
Follow on:
Instagram: Microbe_Mail
X/Twitter: @microbemail
Facebook: MicrobeMail
Tiktok: @microbe.mail
Watch this episode on YouTube: Microbe Mail
E-mail us: [email protected]
WE'D LOVE YOUR FEEDBACK ON THIS EPISODE!
Next Episode
"Would you rather?" The Antibiotics version
We're back with another game of 'Would you rather?' Where we pose a scenario, and our guests give us their views. This episode really challenges the basis of some of the beliefs and practices regarding antimicrobials. Some of the questions are so tricky, who knows if there even is a correct answer. What we do know is... it depends.
About our Guest:
Prof. Andrew Whitelaw worked as a consultant pathologist in clinical microbiology at Groote Schuur Hospital from 2003 – 2012. In December 2012 took up the post of Head of Department of Medical Microbiology at the University of Stellenbosch / Tygerberg Hospital. His early research revolved around molecular characterization of ESBLs in members of the Enterobacteriaceae, and he has been involved in a number of studies and activities related to antimicrobial resistance (AMR) and infection control over the last decade, both for community as well as hospital acquired pathogens. Most relevant among these would be his involvement in the South African Antibiotic Stewardship Programme (SAASP), The Infection Control Society of Southern Africa, and the SA Ministerial Advisory Committee on AMR.
Ongoing research interests focus on antimicrobial resistance in Enterobacteriaceae and Staphylococcus aureus, including molecular epidemiology and mechanisms of resistance as well as clinical impact and control of AMR. He is also involved in studies describing the human microbiota and in particular the effect of antimicrobials on the microbiota.
Resources from this episode:
SASCM C. difficile infection guidelines
WE'D LOVE YOUR FEEDBACK ON THIS EPISODE –
Visit the Microbe Mail website to sign up for updates
Follow on:
Instagram: Microbe_Mail
X/Twitter: @microbemail
Facebook: MicrobeMail
Tiktok: @microbe.mail
Watch this episode on our new YouTube channel: Microbe Mail
E-mail us: [email protected]
Don't forget to also have a listen to these featured episodes:
Episode 43: Communicating antimicrobial therapy to patients
Episode 38: Would you rather?: The mycology version
Episode 35: Would you rather?: The virology version
Episode 33: Would you rather?:The Bacterial version
If you like this episode you’ll love
Episode Comments
Featured in these lists
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/microbe-mail-264842/appropriate-use-of-%ce%b2-lactam-%ce%b2-lactamase-inhibitor-combination-antibiot-51105899"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to appropriate use of β-lactam - β-lactamase inhibitor combination antibiotics on goodpods" style="width: 225px" /> </a>
Copy